FDA Grants Import Discretion of Bracco's Iodinated Contrast Medium Iomeron (iomeprol injection) to Address Supply Shortages

Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage. The product addresses the need for the most advanced diagnostic imaging standards and will be temporarily available in the U.S. market starting at the end of August, 2022.

image.cfm?name=UK-Iomeron-350-500ml-box.jpg&id=745554

Siemens Healthineers Announces FDA Clearance of ARTIS icono ceiling Angiography System

InfiMed's i4DR with Wireless Detector Now Available

IOMERON- iomeprol injection injection, solution

articles • APPLIED RADIOLOGY

CTA Power Injector Adds Data Management System

FDA Grants Import Discretion of Bracco's Iodinated Contrast Medium Iomeron (iomeprol injection) to Address Supply Shortages

IOMERON- iomeprol injection injection, solution

ACIST Features Contrast Injectors, Software